Patient care is at the heart of everything we do at the Greenwood Genetic Center. The field of genetic and genomic medicine is advancing quickly
with breakthroughs happening at an exciting pace. The Greenwood Genetic Center’s JC Self Research Institute of Human Genetics is leading the
way in identifying the causes and mechanisms for autism, birth defects, intellectual disabilities and metabolic diseases.
Research collaboration is key to pool talent and resources for the sharing of discoveries, advancing of technologies and development of treatments
for the good of our patients and their families. Advances in medicine occur faster when researchers, laboratory scientists and clinicians collaborate
to learn more about genetic diseases. Scientists in the Research Division actively share information and discoveries with the other divisions
at GGC as well as with researchers and clinical collaborators from around the world to help GGC reach its goal of reducing the prevalence and
impact of genetic disorders.
Clemson Center for Human Genetics
GGC has joined efforts with the CCHG to expand the genomic capabilities of both Centers through the purchase of a NovaSeq instrument that will
be used to sequence whole genomes. We actively collaborate with the CCHG on numerous research projects, including the use of fruit flies to
model genetic disorders and test how natural variation in the genome can influence disease severity and penetrance.
University of South Carolina
GGC researchers have developed research collaborations with scientists at USC and USC School of Medicine. These interactions range from collaborative
studies on autism and other neurodevelopmental disorders to the training of medical students during summer rotations.
Partnering with Pharmaceutical Companies
In light of our ultimate goal to identify treatments for genetic disorders, researchers at GGC engage in several partnerships with pharmaceutical
companies to develop therapies. Dr. Luigi Boccuto
is actively engaged in projects
with a Swiss pharmaceutical company to identify new treatment strategies for autism and to classify patients with ASD into specific subgroups.
He is also working with Circa Biosciences to develop a quick and reliable blood-based diagnostic test for ASD. Dr. Richard Steet
is also working with pharmaceutical companies to explore new therapies for CDGs and lysosomal storage disorders.